November 16, 2026 · Regulatory Affairs
Decentralized Clinical Trials in Canada: Health Canada's 2026 Guidance
By Mussarat Fatima

On 27 October 2026, Health Canada published its final Guidance for clinical trials with decentralized elements. For sponsors, contract research organizations and trial sites across Canada, this closes a long consultation and sets clear expectations for trials that happen partly, or almost entirely, away from a traditional research centre. If you run drug trials and you use remote visits, electronic consent, home nursing, wearable sensors or direct-to-home shipping of study drug, this guidance now describes how Health Canada expects you to manage them. This article explains what the guidance says, what changed, and the practical steps your quality and clinical operations teams should take now.
Executive summary
Decentralized elements have moved from a pandemic workaround to a standard way of running clinical research. Participants want fewer trips to a hospital, and sponsors want faster recruitment and better retention. The challenge has always been that the Food and Drug Regulations were written for site-based trials, so sponsors were left to interpret how remote consent, home dosing and electronic source data fit the rules. The new guidance removes much of that guesswork.
Health Canada started this work with a draft guidance released on 23 December 2025, took public comments until 21 February 2026, received 35 submissions, and published the final version in October 2026. The guidance sits alongside the interim clinical trial policy that took effect on 14 September 2026 and points ahead to final regulations expected in spring 2027. The practical takeaway for sponsors is to treat decentralized elements as a quality-by-design decision, document the risks and controls in the clinical trial application, and make sure every delegated activity, from a home visit to a shipment of investigational drug, has a clear owner, a procedure and a record. This article walks through the scope, the decentralized elements Health Canada names, the responsibilities it assigns, and a readiness checklist your team can act on.
What is a clinical trial with decentralized elements?
A clinical trial with decentralized elements is a trial that, in Health Canada's words, incorporates activities that are conducted outside traditional clinical trial centres. These trials are sometimes called hybrid, remote or virtual trials. Instead of a participant attending every visit at a hospital or clinic, some activities happen at home, online or through a local health care provider. The trial is not a new regulatory category. It is a conventional drug trial that uses different tools to reach the participant.
Health Canada names several decentralized elements that a protocol may use:
- Remote visits, including telehealth platforms such as online portals and video conferencing.
- Home-based trial activities, such as visits by trial personnel, mobile clinics or home nursing.
- Electronic informed consent processes.
- Technologies that collect remote data, such as wearable sensors and connected medical devices.
- Involvement of local health care providers, for example follow-up visits at a regional treatment centre or testing at a local laboratory.
- Shipping of investigational products closer to participants, including direct-to-home delivery of study drug.
A trial can use one of these elements or several. The more an activity moves away from the site, the more planning Health Canada expects to see. This is the same principle we described when ICH released its decentralized trial annex, covered in our explainer on ICH E6(R3) Annex 2 and decentralized trial compliance in Canada.
What Health Canada published, and when
Why it matters: the dates tell you how settled the guidance is and when binding rules arrive. The guidance is final and in effect now as an expectation. The matching regulatory amendments are still to come, so this is the window to align your systems before compliance becomes mandatory.
| Milestone | Date | What it means |
|---|---|---|
| Draft guidance released for consultation | 23 December 2025 | Health Canada set out its proposed expectations and invited comment. |
| Consultation closed | 21 February 2026 | 35 written submissions were received from sponsors, associations and sites. |
| Interim clinical trial policy in effect | 14 September 2026 | Flexibilities including competency-based qualified investigators began to apply. |
| Final decentralized elements guidance published | 27 October 2026 | The expectations in this article are now in force as administrative guidance. |
| Final regulations expected | Spring 2027 (Canada Gazette, Part II) | Binding amendments, followed by a stated one-year coming-into-force period. |
The interim policy and the decentralized guidance are two parts of the same modernization program. We cover the interim framework, including coordinated research ethics board review and competency-based investigators, in our article on Health Canada's interim clinical trial policy.
Scope: which trials the guidance covers
What to check first: confirm your trial is in scope before you map your controls to this guidance. It applies to human drug trials regulated under Part C, Division 5 of the Food and Drug Regulations. It does not directly apply to medical device, natural health product or food trials, although Health Canada says similar principles apply to those products.
| In scope | Out of direct scope |
|---|---|
| Drug trials in humans: pharmaceuticals, biologics and radiopharmaceuticals | Trials evaluating medical devices |
| Phases I to IV | Trials of natural health products |
| Any party conducting the trial: sponsors, qualified investigators, health care providers, clinical laboratories, academia, CROs and vendors | Trials of foods for special dietary purposes |
| Conducted under Part C, Division 5 of the Food and Drug Regulations | These products are regulated under different regulations, though similar principles apply |
The guidance is an administrative instrument, not a legal one. It explains how Health Canada interprets the existing regulations. The legal obligations still come from the Food and Drug Regulations, which you can read on the Justice Laws website.
The decentralized elements in detail
Each decentralized element carries its own risks. Health Canada's expectation is consistent: identify the risk, build a proportionate control, write it into a procedure, and keep a record that an inspector can follow. Here is how the main elements break down.
Remote and electronic informed consent
Consent is the element Health Canada and research ethics boards watch most closely. Electronic consent is allowed, but the participant must still receive the same information, have the same chance to ask questions, and give consent that is documented and verifiable. Build in identity verification, a way for the participant to reach a qualified person, and a record that captures the version of the consent form used and the date it was signed.
Direct-to-home shipping of investigational drug
Shipping study drug to a participant's home, sometimes called direct-to-participant supply, is one of the harder elements to control. Health Canada notes that local or direct-to-home shipping of investigational drugs is permitted, but that provincial and territorial requirements vary, and that storage and transport conditions must be maintained. Your plan should cover temperature control and monitoring, chain of custody, drug accountability, and what happens if a shipment is delayed or a cold chain excursion occurs. Health Canada points to its guidelines for environmental control of drugs during storage and transportation (GUI-0069) for the conditions that apply.
Home visits, mobile clinics and local health care providers
Activities conducted in a participant's home, at-home visits by trial personnel, and the use of mobile clinics are all contemplated by the guidance. So is the involvement of local health care providers for follow-up visits and local laboratories for sample collection. The key control is delegation. Anyone performing a trial activity must be qualified, trained for that task, and recorded on a delegation log, whether they sit at the main site or visit a participant at home.
Digital health technology and software as a medical device
Wearable sensors, connected devices and telehealth platforms generate trial data. Health Canada expects sponsors and qualified investigators to ensure that all computerized systems and digital health technology used in the trial are fit for purpose, reliable and appropriate. Some tools may themselves meet the definition of software as a medical device, which brings separate obligations. Validate these systems, control access, and make sure the data they produce is attributable, legible, contemporaneous, original and accurate.
Data management and electronic source data
When source data is captured electronically at home or through a device, data integrity is the central risk. Health Canada expects a data management plan that protects participant confidentiality and maintains data integrity, reliability and traceability, with attention to data governance and data residency. The consequences of getting this wrong are not theoretical. We examined how a data integrity failure can unravel an entire approval in our analysis of the Tavneos ADVOCATE trial.
Sponsor and investigator responsibilities
What Health Canada expects: the sponsor remains accountable for the trial, and the qualified investigator remains accountable for the conduct at and from the site, no matter how decentralized the design. The guidance is explicit that standard operating procedures may not be sufficient on their own to ensure the quality of decentralized activities, so sponsors need to think beyond their usual templates.
Health Canada sets out several expectations that sponsors should be able to demonstrate:
- That participant risk is minimized and safety will be appropriately monitored.
- That participants are made aware of the potential risks and benefits.
- That the decentralized elements will help achieve the study objectives, rather than being added for their own sake.
- That quality is built into the design by identifying critical-to-quality factors, in line with ICH E8 general considerations for clinical studies.
- That all computerized systems and digital health technology are fit for purpose, reliable and appropriate.
- That the design offers equitable, participant-centred options, including alternative non-digital options, technology navigation assistance and information technology support, so that participants who are less comfortable with technology are not excluded.
Health Canada also directs readers to the Good clinical practices guidance (GUI-0100), the ICH Guideline for Good Clinical Practice (ICH E6), and the Tri-Council Policy Statement on ethical conduct for research involving humans, TCPS 2 (2022), for the broader ethics and GCP framework.
How this fits the broader clinical trial modernization
The decentralized guidance is one piece of a larger reform. Health Canada is modernizing its entire clinical trial framework, and sponsors should read the decentralized guidance together with the related changes rather than in isolation. The interim policy introduced competency-based qualified investigators, meaning a qualified investigator may be a physician or dentist, or an individual with the right education, training and experience, provided a licensed physician or dentist is responsible for trial-related medical decisions. Separately, Health Canada has begun the phased rollout of structured protocols under ICH M11, which we cover in our guide to ICH M11 CeSHarP and structured protocol templates, and it has set new registration and disclosure duties through the Canadian clinical trials portal. Taken together, these changes reward sponsors who build flexible, well-documented quality systems now.
Decentralized clinical trial compliance checklist
Use this checklist to pressure-test a protocol that includes decentralized elements before you submit a clinical trial application:
- Confirm the trial is a drug trial under Part C, Division 5, and therefore in scope.
- Document, in the application, which decentralized elements you will use and why each one supports the study objectives.
- Complete a risk assessment that identifies critical-to-quality factors and sets proportionate controls.
- Build an electronic consent process with identity verification, participant support and version-controlled records.
- Define the direct-to-home shipping plan, including temperature control, monitoring, chain of custody and accountability.
- Validate every computerized system and digital health technology, and confirm whether any tool is software as a medical device.
- Write a data management plan covering confidentiality, integrity, traceability, data governance and data residency.
- Map roles and responsibilities, and keep a delegation log that includes home-visit staff and local health care providers.
- Provide equitable, non-digital alternatives and technology support so participants are not excluded.
- Plan for Health Canada inspection, with records that let an inspector follow each decentralized activity end to end.
Common mistakes to avoid
- Adding decentralized elements without a reason. Health Canada expects each element to help achieve the study objectives. Convenience alone is not a sufficient justification in the application.
- Relying on existing site SOPs. The guidance warns that standard operating procedures may not be sufficient for decentralized activities. Home visits, shipping and remote consent usually need their own procedures.
- Treating electronic consent as a formality. Weak identity verification or missing version control is a common research ethics board and inspection finding.
- Ignoring provincial differences. Direct-to-home shipping and dispensing requirements vary across provinces and territories, so one national plan may not fit every participant.
- Leaving digital tools unvalidated. Wearables and portals that feed trial data must be validated and controlled, or the data they produce is open to challenge.
- Forgetting equity. A fully digital design can exclude participants who lack devices, connectivity or digital confidence, which undermines both ethics and recruitment.
Frequently asked questions
Is Health Canada's decentralized clinical trials guidance now in effect?
Yes. Health Canada published the final guidance for clinical trials with decentralized elements on 27 October 2026, and it describes current expectations. It is administrative guidance rather than law. Binding regulatory amendments are expected in Canada Gazette, Part II, in spring 2027, with a stated one-year coming-into-force period after that.
Does the guidance apply to medical device or natural health product trials?
Not directly. The guidance applies to human drug trials, meaning pharmaceuticals, biologics and radiopharmaceuticals, under Part C, Division 5 of the Food and Drug Regulations. Medical devices, natural health products and foods for special dietary purposes are regulated under different rules. Health Canada notes that similar principles apply to those products, so the guidance is still a useful reference.
Can we ship investigational drug directly to a participant's home?
Yes, direct-to-home shipping is permitted, but it must be controlled. You need to maintain storage and transport conditions, document chain of custody and drug accountability, and account for the fact that provincial and territorial requirements vary. Health Canada references its storage and transportation guideline, GUI-0069, for the conditions that apply.
Who can be a qualified investigator under the new framework?
Under the interim policy effective 14 September 2026, a qualified investigator may be a physician or dentist, or an individual with the required education, training and experience. Where the investigator is not a physician or dentist, a licensed physician or dentist must be responsible for trial-related medical decisions.
Do we need to revalidate systems we already used during the pandemic?
You need to be able to show that every computerized system and digital health technology in the trial is fit for purpose, reliable and appropriate. If your earlier validation was informal or undocumented, Health Canada's expectation is that you close that gap. Treat validation as an ongoing obligation, not a one-time event.
How should decentralized elements appear in our clinical trial application?
Describe which elements you will use, justify each against the study objectives, and summarize the risk assessment and the controls you have put in place. An application that names the elements but does not show how the risks are managed is likely to attract questions from Health Canada.
How MFLRC can help
At MF License and Regulatory Consultants, we help sponsors, CROs and sites turn this guidance into a working quality system. Our regulatory and quality teams support decentralized trials from design through inspection, including:
- Gap assessments that compare your current trial design against the new guidance and ICH E6 good clinical practice.
- SOP and plan development for electronic consent, direct-to-home shipping, home visits, delegation and data management.
- Computer system validation and digital health technology qualification, including software as a medical device assessments.
- Clinical trial application support, so your decentralized elements are clearly justified and your risk controls are visible to Health Canada.
- Inspection readiness and mock audits that trace each decentralized activity end to end.
Whether you are adding decentralized elements to an existing trial or designing a hybrid study from the start, we can help you do it in a way that protects participants, your data and your submission timeline.
Conclusion
Health Canada's final guidance for clinical trials with decentralized elements gives sponsors something they have wanted for years: a clear statement of how remote and home-based activities fit the existing rules. The requirements have not been lowered. Participant safety, informed consent and data integrity still govern, and the sponsor remains accountable. What has changed is that the path is now mapped. Sponsors who document their decentralized elements, validate their digital tools, and keep delegation and data records that an inspector can follow will be ready not only for today's guidance but for the binding regulations expected in 2027. The work you do now to build a flexible, well-documented quality system is the work that will let you run faster, more participant-friendly trials with confidence.
Sources and references
- Health Canada, Guidance publishes on clinical trials with decentralized elements: Notice (27 October 2026).
- Health Canada, Guidance for clinical trials with decentralized elements (PDF, October 2026).
- Government of Canada, Food and Drug Regulations, Part C, Division 5.
- Health Canada, Good clinical practices guidance (GUI-0100).
- Health Canada, Guidelines for environmental control of drugs during storage and transportation (GUI-0069).
- International Council for Harmonisation, Efficacy guidelines, including ICH E6 and ICH E8.
- Panel on Research Ethics, Tri-Council Policy Statement, TCPS 2 (2022).
Downloadable Resource
Decentralized Clinical Trial Readiness Checklist
A practical, print-ready checklist to prepare your protocol, consent process, shipping plan, digital systems and data management for Health Canada's decentralized elements guidance.
File: MFLRC-Decentralized-Clinical-Trials-Checklist.pdf
Share with others
Tags
